ACTUATE THERAPEUTICS, INC. — Form S-1/A
Filed October 19, 2026 · analyzed by the Registration Agent
S-1/A
— Neutral
significance 18/100
What the filing says
Actuate Therapeutics, Inc. entered into an underwriting agreement with Newbridge Securities Corporation (sole underwriter) for a public offering of common stock, pre-funded warrants, and common warrants. Key terms include: offering structure with Firm Securities and Option Securities (15% over-allotment); underwriter receives 3.5% warrant coverage; underwriter's counsel fees capped at $125,000 (plus $25,000 advance previously paid); 120-day lock-up period for officers/directors, 2-year lock-up for major shareholders (Bios Equity and Kairos Venture funds); registration on Nasdaq Capital Market; underwriter warrants exercisable at 125% of offering price with 5-year term.
Why this rating
IPO underwriting agreement is routine disclosure; document is boilerplate template with blank pricing/share count fields. Relative to $42M market cap, IPO is material, but this filing itself contains no deal-specific dollar amounts or economics—those are blanked out and will appear in prospectus. No concrete transaction size disclosed here.
See more from October 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.